A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Recruiting
Early Phase 1
Interventional Study
Relapsed/Refractory Autoimmune Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 36 (estimated)
- Sponsor
- Nanjing Legend Biotech Co. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* Inclusion Criteria:
1. Subjects voluntary agreement to provide written informed consent.
2. Aged 18 to 70 years, either sex.
3. Clinical laboratory values meet screening criteria.
4. Positive test for CD19 and/ or BCMA
SLE:
* Meets at least 1 classification criteria≥6 months for SLE.
* …
Contacts